Peer-influenced content. Sources you trust. No registration required. This is HCN.

Annals of Internal MedicineCardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes (T2D) w. Sodium–Glucose Cotransporter-2 Inhibitors (SGLT-2i) vs. Metformin

A new study published in Annals of Internal Medicine looks at the link between cardiovascular disease among adults with type 2 diabetes, which might be more prevalent than previously thought. This study compares cardiovascular outcomes in patients taking first line metformin vs. SGLT-2 inhibitors, based on claims data over a 7-year period. SGLT-2 inhibitor use was associated with lower rates of hospitalization for heart failure and all cause mortality. Rates for MI and stroke were similar for the two treatments.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form